Lebrikizumab for severe prurigo nodularis
Treatments studied
Part of Skin clinical trials.
This study tests a drug called lebrikizumab for people with severe prurigo nodularis, a condition with very itchy skin bumps. The drug is given as an injection and aims to reduce itching and clear the bumps faster.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 80 years old.
- You have had prurigo nodularis for at least 1 year.
- You have moderate-to-severe itching with multiple nodules on at least two body areas.
- You have not taken lebrikizumab before and are not currently using other treatments for prurigo nodularis.
- You don't have HIV, hepatitis, a parasitic infection, or a history of anaphylaxis.
- You are not pregnant or breastfeeding, and you agree to use birth control if needed.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental drug called ICP-332 for people with prurigo nodularis (a condition causing very itchy, hard bumps on the skin). It aims to see if the drug can safely reduce itching and improve skin lesions.
This study follows people with moderate-to-severe prurigo nodularis who are starting dupilumab. It looks at how the medicine works over time and how it affects the immune system, to help understand long-term benefits.
This study tests whether lebrikizumab, a new injection, can reduce nummular eczema (coin-shaped eczema patches) in adults whose condition hasn't improved with topical steroid creams. It's designed to help people with moderate-to-severe nummular eczema who need a stronger treatment option.
This study looks at how well nemolizumab works in real-world settings for adults with moderate-to-severe prurigo nodularis, a skin condition that causes intense itching and bumps. If you are starting this medication as part of your normal care, you may be able to join.
This study tests whether the medication dupilumab can safely reduce itching and skin bumps in children aged 6 months to under 18 years who have prurigo nodularis, a skin condition that causes intense itching and nodules. Participation involves taking the study drug and tracking itch daily.
This trial tests an injection called SHR-1819 for adults with prurigo nodularis, a skin condition with itchy bumps. The goal is to see if it helps reduce itching and bumps.
Hear when a new Prurigo Nodularis (PN) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.